Mineralys Therapeutics (MLYS) said Monday that lorundrostat met primary endpoints in phase 3 Launch-HTN and phase 2 Advance-HTN trials in patients with uncontrolled hypertension or resistant hypertension.
Shares surged 73% as intraday trading volume soared to more than 12.4 million from a daily average of about 283,000.
Rocket (RKT) said Monday it will buy real-estate brokerage Redfin (RDFN) for an equity value of $1.75 billion to drive users to its home-lending business.
Shares of Redfin soared 65% as intraday trading volume catapulted to more than 81.1 million from a daily average of about 5.5 million.
Protagonist Therapeutics (PTGX) and Johnson & Johnson (JNJ) said a phase 2b study of the investigational targeted oral peptide icotrokinra in adults with moderately to severely active ulcerative colitis met the primary endpoint of clinical response in three dose levels at week 12, with a "favorable" safety profile.
Shares of Protagonist advanced 45%, with intraday trading volume rising to over 3.9 million compared with a daily average of about 725,000.
Price: 18.23, Change: +7.71, Percent Change: +73.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.